1
|
Zhang C, Jia B, Zhu Y, Zhu SC. Human-level few-shot concept induction through minimax entropy learning. Sci Adv 2024; 10:eadg2488. [PMID: 38640235 PMCID: PMC11029807 DOI: 10.1126/sciadv.adg2488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Accepted: 03/14/2024] [Indexed: 04/21/2024]
Abstract
Humans learn concepts both from labeled supervision and by unsupervised observation of patterns, a process machines are being taught to mimic by training on large annotated datasets-a method quite different from the human pathway, wherein few examples with no supervision suffice to induce an unfamiliar relational concept. We introduce a computational model designed to emulate human inductive reasoning on abstract reasoning tasks, such as those in IQ tests, using a minimax entropy approach. This method combines identifying the most effective constraints on data via minimum entropy with determining the best combination of them via maximum entropy. Our model, which applies this unsupervised technique, induces concepts from just one instance, reaching human-level performance on tasks of Raven's Progressive Matrices (RPM), Machine Number Sense (MNS), and Odd-One-Out (O3). These results demonstrate the potential of minimax entropy learning for enabling machines to learn relational concepts efficiently with minimal input.
Collapse
Affiliation(s)
- Chi Zhang
- Beijing Institute for General Artificial Intelligence (BIGAI), Beijing, 10080, China
| | - Baoxiong Jia
- Beijing Institute for General Artificial Intelligence (BIGAI), Beijing, 10080, China
| | - Yixin Zhu
- Institute for Artificial Intelligence, Peking University, Beijing, 10080, China
| | - Song-Chun Zhu
- Beijing Institute for General Artificial Intelligence (BIGAI), Beijing, 10080, China
- Institute for Artificial Intelligence, Peking University, Beijing, 10080, China
| |
Collapse
|
2
|
Shi WP, Jia B, Jiang YP, Liu D, Wang YZ, Zhang HN, Li T. Lateral retraction could achieve better early postoperative knee function than patellar eversion in total knee arthroplasty: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2023; 27:5059-5069. [PMID: 37318480 DOI: 10.26355/eurrev_202306_32623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
OBJECTIVE Comparisons between patellar eversion (PE) and lateral retraction (LR) in total knee arthroplasty (TKA) are still inconclusive. To determine the most suitable procedure, we aimed to evaluate the safety and efficacy of PE and LR in TKA in this meta-analysis. MATERIALS AND METHODS This meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Web-based literature databases, including WANFANG, VIP, CNKI, the Cochrane Library, Embase, and PubMed, were utilized to conduct a comprehensive literature search for studies published until June 2022 that compared PE with LR in primary TKA. The quality of the selected randomized controlled trials (RCTs) was evaluated using guidelines of the Cochrane Reviews Handbook 5.0.2. RESULTS A total of 10 RCTs, including 782 patients and 823 TKAs, were selected in this meta-analysis. Our results showed that using LR improved postoperative knee extensor function and range of motion (ROM). In addition, PE and LR resulted in similar clinical benefits in terms of Knee Society Function score, pain, length of hospital stay, Insall-Salvati ratio, the occurrence of patella baja, and complications related to the operation. CONCLUSIONS Existing evidence suggested that using LR in TKA improved early postoperative knee function. Similar clinical and radiographic outcomes were obtained 1 year after the procedures were performed. Based on these findings, we recommended the use of LR in TKA. However, studies with large sample sizes are needed to validate these findings.
Collapse
Affiliation(s)
- W-P Shi
- Department of Joint Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
| | | | | | | | | | | | | |
Collapse
|
3
|
Jia B, Zhao J, Jin B, Zhang F, Wang S, Zhang L, Wang Z, An T, Wang Y, Zhuo M, Li J, Yang X, Li S, Chen H, Chi Y, Wang J, Zhai X, Tai Y, Liu Y, Guan G. 36P Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: A real-world multi-center study. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00290-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
4
|
Morand EF, Tanaka Y, Furie R, Vital E, van Vollenhoven R, Kalunian K, Mosca M, Dörner T, Wallace DJ, Silk M, Dickson C, De La Torre I, Meszaros G, Jia B, Crowe B, Petri MA. POS0190 EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1968] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundIn a 24-week, phase 2 clinical study (NCT02708095) in patients with systemic lupus erythematosus (SLE), baricitinib (BARI), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, inhibited the type l interferon gene signature, multiple other cytokine pathways, and improved disease activity (1) (2).ObjectivesTo further evaluate the efficacy and safety of BARI in patients with SLE.MethodsPatients with active SLE receiving stable background therapy were randomised 1:1:1 to BARI 2-mg, 4-mg, or placebo (PBO) once daily in two identically designed, 52-week, phase 3 randomised, PBO-controlled studies. In SLE-BRAVE-I (NCT03616912) and -II (NCT03616964), 760 and 775 patients, respectively were enrolled in a balanced manner across regions, although different countries per region participated in each study. The primary endpoint for both studies was the proportion of patients achieving an SLE Responder Index-4 (SRI-4) response at week 52. Glucocorticoid tapering was encouraged but not required per protocol.ResultsThe mean Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) at baseline was 10.1 for both SLE-BRAVE-I and -II participants; musculoskeletal and mucocutaneous domains were the most common domains involved at baseline. In SLE-BRAVE-I, the proportion of SRI-4 responders at week 52 among patients treated with BARI 4-mg (56.7%), but not BARI 2-mg (49.8%), was significantly greater than in patients treated with PBO (45.9%, p = 0.016) (Table 1). No difference was seen in SLE-BRAVE-II (47.1%, 46.3%, and 45.6%, BARI 4-mg, 2-mg, and PBO, respectively). None of the key secondary endpoints, including glucocorticoid tapering or time to first severe flare (SFI), were met in either study. The proportions of patients with serious adverse events (SAEs) were 7.1% and 8.6% for PBO, 9.4% and 13.4% for BARI 2-mg and 10.3% and 11.2% for BARI 4-mg in SLE-BRAVE-I and II, respectively.Table 1.Efficacy and safety of baricitinib in patients with SLE-BRAVE-I and -IISLE-BRAVE-ISLE-BRAVE-IIEfficacy measurePBO (N=253)BARI 2-mg (N=255)BARI 4-mg (N=252)PBO (N=256)BARI 2-mg (N=261)BARI 4-mg (N=258)SRI-4 (W52)116 (45.9)126 (49.8)142 (56.7)*116 (45.6)120 (46.3)121 (47.1)SRI-4 (W24)99 (39.1)114 (44.8)117 (46.5)98 (38.6)104 (40.0)108 (42.1)Severe Flares (n, events)38 (15.0)34 (13.3)26 (10.3)26 (10.2)29 (11.1)29 (11.2)HR for time to first severe flare (SFI) HR [CI]NA0.8 [0.52, 1.32]0.65 [0.40, 1.08]NA1.1 [0.65, 1.89]1.1 [0.67, 1.94]Glucocorticoid sparing36 (30.8)31 (29.2)36 (34.0)33 (31.7)34 (29.8)36 (34.3)LLDAS (W52)66 (26.2)65 (25.7)74 (29.7)59 (23.2)62 (24.0)65 (25.4)Safety measureTEAE210 (83.0)210 (82.4)208 (82.5)198 (77.3)199 (76.2)200 (77.5)SAE18 (7.1)24 (9.4)26 (10.3)22 (8.6)35 (13.4)29 (11.2)Data are n (%) patients, unless otherwise indicated. BARI=baricitinib; CI=confidence interval; HR=hazard ratio compared with PBO; LLDAS=lupus low disease activity state; N=number of patients in the analysis population; n=number of patients in the specified category; PBO=placebo; TEAE=treatment-emergent adverse event; SAE=serious adverse event; W=week. *p≤0.05 vs PBO.ConclusionAlthough phase 2 data suggested BARI as a potential treatment for patients with SLE (2), the SLE-BRAVE-I and -II phase 3 study results were discordant for the primary outcome measure, with only SLE-BRAVE-I positive, making it difficult to elucidate benefit. Additional analyses are being performed to understand this discordance. No new safety signals were observed.References[1]Dörner T, Tanaka Y, et al. Lupus Sci Med. 2020;7(1).[2]Wallace DJ, Furie RA, et al. Lancet. 2018;392(10143):222-31.Disclosure of InterestsEric F. Morand Speakers bureau: Astra Zeneca, Eli Lilly, Novartis, Sanofi, Consultant of: Amgen, AstraZeneca, Asahi Kasei, Biogen, BristolMyersSquibb, Capella, Eli Lilly, EMD Serono, Genentech, Glaxosmithkline, Janssen, Neovacs, Sanofi, Servier, UCB, Wolf, Grant/research support from: Janssen, AstraZeneca, BristolMyersSquibb, Eli Lilly, EMD Serono, GlaxoSmithKline, Yoshiya Tanaka Speakers bureau: Gilead, Abbvie, Behringer-Ingelheim, Eli Lilly, Mitsubishi-Tanabe, Chugai, Amgen, YL Biologics, Eisai, Astellas, Bristol-Myers, Astra-Zeneca, Consultant of: Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GSK, Abbvie, Grant/research support from: Asahi-Kasei, Abbvie, Chugai, Mitsubishi-Tanabe, Eisai, Takeda, Corrona, Daiichi-Sankyo, Kowa, Behringer-Ingelheim, Richard Furie Consultant of: Eli Lilly, Edward Vital Consultant of: Eli Lilly (consultant and honoraria), Ronald van Vollenhoven Consultant of: Abbvie, Biotest, BMS, Celgene, Crescendo, Eli Lilly and Company, GSK, Janssen, Merck, Novartis, Pfizer, Roche, UCB, Vertex, Grant/research support from: Abbvie, Amgen, BMS, GSK, Pfizer, Roche, UCB, Kenneth Kalunian Consultant of: Eli Lilly, Marta Mosca Consultant of: Eli Lilly, GSK, Astra Zeneca, Thomas Dörner Speakers bureau: AbbVie, Eli Lilly, BMS, Novartis, BMS/Celgene, Janssen, Consultant of: AbbVie, Eli Lilly, BMS, Novartis, BMS/Celgene, Janssen, Daniel J. Wallace Consultant of: Amgen, Eli Lilly and Company, EMD Merck Serono, and Pfizer, Maria Silk Shareholder of: Eli Lilly, Employee of: Eli Lilly, christina dickson Shareholder of: Eli Lilly, Employee of: Eli Lilly, Inmaculada De La Torre Shareholder of: Eli Lilly, Employee of: Eli Lilly, Gabriella Meszaros Shareholder of: Eli Lilly, Employee of: Eli Lilly, Bochao Jia Shareholder of: Eli Lilly, Employee of: Eli Lilly, Brenda Crowe Shareholder of: Eli Lilly, Employee of: Eli Lilly, Michelle A Petri Consultant of: Eli Lilly
Collapse
|
5
|
Jia B, Fei C, Ren J, Wang M, He JL, Xu ZC, Lu YF, Qi L, Liao YH, Qiao F. [Clinical study of digital six-axis external fixation frame based on CT data for tibiofibular fractures]. Zhonghua Wai Ke Za Zhi 2022; 60:552-557. [PMID: 35658342 DOI: 10.3760/cma.j.cn112139-20211206-00580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To investigate the clinical effect of applying the digital six-axis external fixation frame based on CT data in the treatment of tibiofibular fractures. Methods: The clinical data of 43 patients with tibiofibular fractures treated by the self-developed digital six-axis external fixation frame based on CT data at Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital from January 2018 to January 2021 were retrospective analysis.There were 27 males and 16 females,aged (36.0±9.4) years(range:25 to 50 years).AO classification:15 cases of 42A,11 cases of 42B, and 17 cases of 42C.There were 7 open fractures and Gustilo fracture classification:2 cases of type Ⅰ,4 cases of type Ⅱ,and 1 case of type Ⅲ.The two or three plane rings were connected with six connecting rods to form a complete six-axis external fixation frame,and the distal and proximal fracture blocks were connected to the distal and proximal rings by fixation pins,and the lengths of the six connecting rods needed to be adjusted were calculated by using the supporting software according to the CT data after surgery,and then the lengths of the connecting rods were adjusted one by one to complete the reduction of the fracture. The reduction accuracy of this six-axis external fixation brace was evaluated by measuring postoperative radiographs; postoperative recovery and complications were collected,the time of brace removal was recorded,and the function of the affected limb was evaluated according to the Johner-Wruhs score at the final follow-up. Results: Postoperative radiographs showed that all patients achieved satisfactory reduction with lateral displacement(M(IQR)) of 2.3(2.5) mm (range:0.3 to 7.3 mm),anteroposterior displacement of 2.1 (2.4) mm (range:0.3 to 5.7 mm),anteroposterior angulation of 2.5(2.4)°(range:0 to 5°),internal and external angulation of 2.1(1.5)°(range:0 to 4°), and no significant internal or external rotational deformity was detected on the exterior.On the second postoperative day,all patients were able to walk with partial weight-bearing on crutches. All 43 patients were followed up for more than 6 months,with a follow-up period of (33.3±7.3) weeks (range:24 to 42 weeks).The external fixation frame was removed after the fracture healed.The external frame was removed at 20(3)weeks (range:18 to 25 weeks) postoperatively. Up to the final follow up, no secondary fracture occurred in any of them.The Johner-Wruhs score of the affected limb at the last follow-up was excellent in 39 cases and good in 4 cases. Conclusion: The digital six-axis external fixator based on CT data for tibiofibular fractures has the advantages of precise reduction,firm fixation,simple operation,rapid fracture healing,and minimal trauma, which is a minimally invasive method for treating tibiofibular fractures,especially suitable for patients with poor skin and soft tissue conditions such as open injuries.
Collapse
Affiliation(s)
- B Jia
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - C Fei
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - J Ren
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - M Wang
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - J L He
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - Z C Xu
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - Y F Lu
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - L Qi
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - Y H Liao
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| | - F Qiao
- Integrated Orthopedic Department of Traditional Chinese Medicine (TCM) and Western Medicine,HongHui Hospital, Xi'an Jiaotong University, Xi'an 710054, China
| |
Collapse
|
6
|
Jia B, Wang CG, Chen H, Zhou XB, Qian K, Chen C, Xu LX, Fu JL. The effect of cytoplasmic dynein on the development and functional maintenance of retinal photoreceptor cells. Eur Rev Med Pharmacol Sci 2021; 25:6539-6547. [PMID: 34787856 DOI: 10.26355/eurrev_202111_27096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Cytoplasmic dynein is a multi-subunit complex that includes cytoplasmic dynein-1 (dynein1) and cytoplasmic dynein-2 (dynein2). It participates in various basic cellular processes, including nuclear migration, mitotic spindle organization, chromosome separation during mitosis, and the location and function of numerous intracellular organelles. Retinal photoreceptor cells are terminally differentiated neurons that cannot regenerate and cannot be replaced once lost. It is thus crucial to study their development to facilitate the generation and improvement of photoreceptor disease treatments. The outer segment (OS) of photoreceptor cells is a specific sensory cilium. An increasing number of studies have shown that cytoplasmic dynein plays an essential role in the development of retinal photoreceptor cells. To date, people have done a lot of studies on the various functions of dynein in cells and have a very detailed understanding. However, the role of dynein in retinal photoreceptor cells has not been summarized in detail. This article summarizes the currently available knowledge relating to the effects and mechanisms of cytoplasmic dynein on the development and functional maintenance of retinal photoreceptor cells.
Collapse
Affiliation(s)
- B Jia
- Department of Ophthalmology, The Second Hospital of Jilin University, Changchun City, China.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Yan C, Wang M, Sun F, Cao L, Jia B, Xia Y. Macrophage M1/M2 ratio as a predictor of pleural thickening in patients with tuberculous pleurisy. Infect Dis Now 2021; 51:590-595. [PMID: 34581278 DOI: 10.1016/j.idnow.2020.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 11/23/2020] [Accepted: 11/27/2020] [Indexed: 10/22/2022]
Abstract
We evaluated the association between macrophage polarization and the development of pleural thickening in patients with tuberculous pleurisy. Patients with tuberculous pleurisy admitted to our hospital between October 2018 and March 2019 were prospectively recruited. Pleural fluid samples were obtained before treatment for detection of adenosine deaminase (ADA) and macrophage phenotype (M1: CD14+ CD86+; M2: CD14+ CD163+). Peripheral blood samples were subjected to interferon gamma release assay (IGRA). All subjects were administered standard anti-tuberculosis regimen (2HREZ/4HR); high-resolution CT was performed to determine pleural thickening (thickness>2mm) after completion of treatment. Pleural effusion in patients with thickened pleura had significantly more M1 but fewer M2 macrophages, and higher ADA level, as compared to those with normal pleura (P<0.05). No significant between-group difference was observed with respect to IGRA. In receiver operating characteristic (ROC) curve analysis, the optimal cut-off level of M1/M2 ratio for predicting pleural thickening was 1.149 (area under the curve: 0.842; sensitivity: 88.6%; specificity: 69.2%; positive predictive value: 86.3%; negative predictive value: 81.7%). M1/M2 ratio in the pleural fluid is a promising marker for predicting the development of pleural thickening in patients with tuberculous pleurisy. Macrophage-mediated immune response may play an important role in the pathogenesis of tuberculous pleurisy.
Collapse
Affiliation(s)
- C Yan
- Department of Respiratory Diseases, the First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, China
| | - M Wang
- Xinjiang Medical University, 830054 Urumqi, Xinjiang, China
| | - F Sun
- Department of Respiratory Diseases, the First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, China.
| | - L Cao
- Department of Clinical Laboratory, the First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, China
| | - B Jia
- Department of Respiratory Diseases, the First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, China
| | - Y Xia
- Department of Respiratory Diseases, the First Affiliated Hospital of Xinjiang Medical University, 830054 Urumqi, Xinjiang, China
| |
Collapse
|
8
|
Qi S, Jia B, Huang S, Wei P, Zhu SC. A Generalized Earley Parser for Human Activity Parsing and Prediction. IEEE Trans Pattern Anal Mach Intell 2021; 43:2538-2554. [PMID: 32142420 DOI: 10.1109/tpami.2020.2976971] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Detection, parsing, and future predictions on sequence data (e.g., videos) require the algorithms to capture non-Markovian and compositional properties of high-level semantics. Context-free grammars are natural choices to capture such properties, but traditional grammar parsers (e.g., Earley parser) only take symbolic sentences as inputs. In this paper, we generalize the Earley parser to parse sequence data which is neither segmented nor labeled. Given the output of an arbitrary probabilistic classifier, this generalized Earley parser finds the optimal segmentation and labels in the language defined by the input grammar. Based on the parsing results, it makes top-down future predictions. The proposed method is generic, principled, and widely applicable. Experiment results clearly show the benefit of our method for both human activity parsing and prediction on three video datasets.
Collapse
|
9
|
Dörner T, Van Vollenhoven R, Doria A, Jia B, Fantini D, Ross Terres J, Silk M, De Bono S, Fischer P, Wallace DJ. POS0686 BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease severity in adults with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase 2 trial1. There were no meaningful reductions in least squares mean change from baseline (BL) in levels of serologic biomarkers for SLE with BARI treatment, including anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies and complement component (C)3 and C41.Objectives:Evaluate the median change from BL in serologic biomarkers in subgroups and the overall population of BARI-treated SLE patients, in addition to the Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response by normalization of anti-dsDNA.Methods:Data were assessed from the phase 2 trial JAHH (NCT02708095). The median change from BL in anti-dsDNA, IgG, C3, and C4 was evaluated over time among the following populations at BL: anti-dsDNA positive (≥30 IU/mL), low C3 (<90 mg/dL), low C4 (<10 mg/dL), and all patients for IgG. Statistical tests were conducted for BARI 2-mg and 4-mg compared with placebo (PBO). Among patients who were anti-dsDNA positive at BL, SRI-4 responder rate was compared for those who stayed positive or achieved normal levels by Week (Wk) 24.Results:Among patients who were anti-dsDNA positive at BL, significant decreases of anti-dsDNA antibodies were observed for BARI 2-mg and 4-mg compared to PBO beginning at Wks 2 and 4, respectively, and continuing through Wk 24 (Figure 1 and Table 1). Moreover, reductions of IgG levels were found for BARI-treated patients including significant decreases for BARI 4-mg compared to PBO at Wks 12 and 24 (Table 1). Among patients who had low levels of C3 and C4 at BL, no significant differences in median change from BL were observed over time with BARI compared to PBO. For patients who were anti-dsDNA positive at BL, no relationship in SRI-4 responder rate was observed for those who stayed positive or achieved normal levels by Wk 24, possibly due to the limited sample size.Conclusion:BARI treatment resulted in a rapid and sustained significant decrease in anti-dsDNA antibodies compared to PBO among anti-dsDNA positive SLE patients at BL, as well as a significant decrease in IgG levels in the 4-mg group at Wks 12 and 24. These data suggest that BARI may have an effect on B cell activity in SLE.References:[1]Wallace D et al. Lancet. 2018;392:222-231.Table 1.PBOBARI 2-mgBARI 4-mgWeek412244122441224Anti-dsDNA (IU/mL)a0.2 (-17.2, 17.3)2.6 (-14.8, 18.4)3.0 (-14.9, 28.3)-15.4** (-31.4, 1.9)-18.1* (-42.0, 4.1)-29.6** (-55.1, 10.3)-17.9** (-42.7, 1.8)-23.3*** (-50.9, -5.9)-15.1** (-71.9, -4.6)IgG (g/L)b-0.31 (-1.1, 0.4)0.09 (-1.1, 0.7)-0.04 (-0.9, 0.9)-0.60 (-1.3, 0.6)-0.30 (-1.3, 0.4)-0.51 (-1.7, 0.6)-0.56 (-1.2, 0.2)-0.65** (-1.3, 0.2)-0.60** (-1.7, 0.2)Data are median change from baseline (25th, 75th percentiles). aData were assessed for patients that were anti-dsDNA positive (≥30 IU/mL) at baseline (PBO N=51, BARI 2-mg N=56, BARI 4-mg N=53). bData were assessed for all patients (PBO N=105, BARI 2-mg N=105, BARI 4-mg N=104). *p≤0.05, **p≤0.01, ***p≤0.001 for BARI vs. PBO.Acknowledgements:The authors would like to acknowledge Nicole L. Byers, of Eli Lilly and Company, for medical writing and process support.Disclosure of Interests:Thomas Dörner Speakers bureau: Eli Lilly and Company, Roche, and Samsung, Consultant of: AbbVie, Celgene, Eli Lilly and Company, Janssen, Novartis, Roche, Samsung, and UCB, Grant/research support from: Janssen, Novartis, Roche, Sanofi, and UCB, Ronald van Vollenhoven Consultant of: Abbvie, Biotest, BMS, Celgene, Crescendo, Eli Lilly and Company, GSK, Janssen, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, Grant/research support from: Abbvie, Amgen, BMS, GSK, Pfizer, Roche, and UCB, Andrea Doria Speakers bureau: GSK, Janssen, Pfizer, and Roche, Consultant of: Celgene, Eli Lilly and Company, and GSK, Bochao Jia Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Damiano Fantini Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Jorge Ross Terres Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Maria Silk Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Stephanie de Bono Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter Fischer Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Daniel J. Wallace Consultant of: Amgen, Aurunia, Eli Lilly and Company, EMD Merck Serono, GSK, and Pfizer
Collapse
|
10
|
Strand V, Sebba A, Jia B, Birt J, Quebe A, Zhang H, Taylor PC. POS0646 RAPID AND CONCURRENT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OF RHEUMATOID ARTHRITIS WITH BARICITINIB IN RA-BEAM. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.65] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:The efficacy and safety of baricitinib (BARI), an oral selective Janus kinase (JAK)1/JAK2 inhibitor, were evaluated in the randomized, controlled trial, RA-BEAM (NCT01710358), in patients (pts) with active rheumatoid arthritis (RA) and inadequate responses (IR) to methotrexate (MTX).1,2,3Objectives:To compare the time to onset and magnitude of improvement across different patient-reported outcomes (PROs) of BARI, adalimumab (ADA) and placebo (PBO) during the first 12 weeks of treatment in RA-BEAM.Methods:1,305 patients on stable background MTX were randomized 3:3:2 to PBO, BARI 4 mg, or ADA 40 mg. In this intent-to-treat analysis, least-squares mean changes and percentage changes from baseline were assessed up to Week 12 for pain (0-100 mm visual analog scale [VAS]), SF-36 physical component summary (PCS, 0-100), morning joint stiffness (MJS) severity (0-10), Health Assessment Questionnaire-Disability Index (HAQ-DI, 0-3), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F, 0-52), and Patient Global Assessment of disease activity (PtGA, 0-100 mm VAS) scores. PROs were compared between treatments with ANCOVA; the model included change from baseline as the response variable, baseline of interest, regional baseline, joint erosion status, and treatment as explanatory variables. Last-observation-carried-forward was applied to impute missing data. Speed of onset and magnitude of PRO improvement are presented in spydergrams.Results:Statistically significant improvements (P<0.05) with BARI and ADA vs. PBO were reported as early as Week 1 for pain, MJS severity, HAQ-DI, and PtGA and at Week 4 for FACIT-F and SF-36 PCS scores. Statistically significantly larger improvements (P<0.05) with BARI vs. ADA were observed as early as Week 2 for pain, PtGA, Week 3 for MJS severity, and Week 4 for HAQ-DI and SF-36 PCS scores. These improvements were maintained to Week 12.Conclusion:Among MTX-IR pts, BARI and ADA treatment resulted in improvements across all PROs by Week 4, and as early as Week 1, for all but FACIT-F and SF-36 PCS scores. Statistically significant larger improvements for BARI compared with ADA were reported for all PROs, except FACIT-F, by Week 12.References:[1]Taylor et al. NEJM, 2017;376: 652-62[2]Keystone et al. Ann Rheum Dis, 2017;76:1853-61[3]Strand et al. Ann Rheum Dis, 2020; 79: 599-600Table 1.Change from baseline in patient-reported outcomes at Weeks 4 and 12Week 4Week 12LSM Change from BaselinePBOADABARIPBOADABARIPain VAS-12.6-22.3***-27.1***††-17.1-26.4***-31.5***††SF-36 PCS3.05.7***6.9***††4.27.2***8.7***††MJS severity-0.9-1.5***-1.9***††-1.4-2.0***-2.5***†††HAQ-DI-0.26-0.47***-0.54***†-0.34-0.56***-0.66***††FACIT-F5.26.9**7.8***6.78.7***9.1***PtGA-14.2-23.7***-26.8***†-16.7-26.6***-31.2***††*p≤0.05, **p≤0.01, ***p≤0.001 vs PBO; †p≤0.05, ††p≤0.01, †††p≤0.001 vs. ADAADA: adalimumab; BARI: baricitinib; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI: Health Assessment Questionnaire-Disability Index; MJS: morning joint stiffness; PBO: placebo; PCS: physical component scale; PtGA: Patient Global Assessment; VAS: visual analog scaleFigure 1.Percentage improvement from baseline to Week 12 in PROs of patients with RA in RA-BEAMAcknowledgements:The authors would like to acknowledge Molly Tomlin, with Eli Lilly and Company, for medical writing and project management supportDisclosure of Interests:Vibeke Strand Consultant of: AbbVie, Amgen, Arena, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly and Company, Galapagos NV, Genentech, Gilead, GlaxoSmithKline, Ichnos, Inmedix, Janssen, Kiniksa, Merck, Myriad Genetics, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sun Pharma, and UCB Pharma, Anthony Sebba Speakers bureau: Eli Lilly and Company, Genentech, Sanofi, Regeneron, Consultant of: Amgen, Eli Lilly and Company, Genentech, Gilead Sciences, Novartis, Sanofi, Regeneron, Bochao Jia Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Julie Birt Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Amanda Quebe Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Hong Zhang Consultant of: Eli Lilly and Company, Peter C. Taylor Consultant of: AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, BMS, Pfizer, Roche, Celltrion, Sanofi, Nordic Pharma, Fresenius and UCB, Grant/research support from: Celgene, Galapagos, Janssen, Lilly
Collapse
|
11
|
Taylor PC, Blanco R, Ikeda K, Jia B, Chen YF, Walls C, Haladyj E, Fautrel B. POS0649 BARICITINIB PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ACROSS ALL DISEASE ACTIVITY LEVELS COMPARED TO PLACEBO AND ADALIMUMAB IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Baricitinib (BARI) is a JAK1/JAK2 inhibitor which provides improvements to clinical signs, symptoms, and patient-reported outcomes (PROs) in patients with rheumatoid arthritis [1, 2].Objectives:The effect of BARI on the relationship between disease activity and pain has been explored previously [3]. The purpose of this post hoc analysis was to determine the association between additional PROs (physical function, fatigue, and duration of morning joint stiffness) and disease activity status after 12 weeks of treatment and to evaluate whether patients with an inadequate response to methotrexate treated with BARI 4 mg experienced greater PRO improvement than patients treated with either placebo (PBO) or adalimumab (ADA) across all levels of disease activity.Methods:Data for these analyses were derived from the Phase 3 study RA-BEAM (N=1305; NCT01710358). Pain was evaluated using a 0-100 mm visual analog scale, physical function was assessed using the Health Assessment Questionnaire-Disability Index (HAQ-DI), fatigue was measured using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale, and duration of morning joint stiffness (MJS, minutes) was reported by the patient. Disease activity was measured using the Clinical Disease Activity Index (CDAI) and categorized as remission (REM, ≤2.8), low disease activity (LDA, >2.8 to ≤10), moderate disease activity (MDA, >10 to ≤22), or high disease activity (HDA, >22). Linear regression was used to model the relationship between change in PROs at Week 12 (response) and CDAI values at Week 12 (primary explanatory variable) to evaluate the extent of improvement in PROs with BARI relative to PBO and ADA across a spectrum of disease activity levels. Last observation carried forward was used to impute missing values.Results:At baseline, 91% of patients were classified as having HDA and 9% as having MDA by CDAI across all treatment groups. After 12 weeks of treatment, 2%, 7%, and 9% of patients achieved REM; 16%, 27%, and 33% of patients achieved LDA; and 33%, 40%, and 38% of patients achieved MDA with PBO, ADA, and BARI, respectively [3].At Week 12, the estimated changes in measures of pain and physical function, as well as duration of MJS, for BARI 4 mg were greater than both PBO and ADA at all disease activity level threshold values of CDAI (Table 1). The estimated change in fatigue for BARI 4 mg was similar to that of ADA, and greater than PBO, at all disease activity level threshold values (Table 1).Table 1.Estimate of PRO Improvement by Disease Activity Threshold Level (CDAI) at Week 12PROCDAI=2.8CDAI=10CDAI=22PBOADABARI4 mgPBOADABARI 4 mgPBOADABARI 4 mgPain VASa(mm)-28.4-37.9-40.9-24.5-32.6-36.1-18.0-23.7-28.1HAQ-DIb-0.6-0.7-0.9-0.5-0.7-0.7-0.4-0.5-0.6FACIT-Fc9.811.811.18.810.610.27.08.78.7Duration of MJS (min)-6.9-37.8-64.9-6.3-35.3-55.7-5.3-31.3-40.2aPain VAS scores range from 0 (no pain) to 100 (worst pain).bHAQ-DI scores range from 0 (no disability) to 3 (completely disabled).cFACIT-F scores range from 0 (worst fatigue) to 52 (no fatigue).Abbreviations: ADA, adalimumab; BARI, baricitinib; CDAI, Clinical Disease Activity Index; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; MJS, morning joint stiffness; PBO, placebo; PRO, patient-reported outcomes; VAS, visual analog scale.Conclusion:Estimates of treatment differences suggest that patients treated with BARI 4 mg may experience greater improvements in pain, physical function, and MJS duration than patients treated with PBO or ADA regardless of their disease activity status reached after 12 weeks of treatment. Using this approach, improvements in fatigue with BARI 4 mg may be greater than with PBO and similar to ADA after 12 weeks.References:[1]Taylor, P.C., et al., N Engl J Med, 2017. 376(7): p. 652-662.[2]Keystone, E.C., et al., Ann Rheum Dis, 2017. 76(11): p. 1853-1861.[3]Taylor, P., et al., Arthritis Rheumatol, 2019. 71(S10): p. 2455-2457.Acknowledgements:The authors would like to acknowledge Catherine Lynch, with Eli Lilly and Company, for medical writing and project management support.Disclosure of Interests:Peter C. Taylor Consultant of: AbbVie, Biogen, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, BMS, Pfizer, Roche, Celltrion, Sanofi, Nordic Pharma, Fresenius and UCB, Grant/research support from: Celgene, Galapagos, Gilead, Eli Lilly, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, BMS, Janssen, Eli Lilly and MSD, Consultant of: Abbvie, Pfizer, Roche, BMS, Janssen, Eli Lilly and MSD, Grant/research support from: Abbvie, MSD, and Roche, Kei Ikeda Speakers bureau: Eli Lilly, Abbvie, Mitsubishi-Tanabe, Novartis, Paid instructor for: Abbvie, Grant/research support from: Mitsubishi-Tanabe, Bochao Jia Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Yun-Fei Chen Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Chad Walls Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Ewa Haladyj Employee of: Eli Lilly and Company, Bruno Fautrel Speakers bureau: Eli Lilly, Consultant of: AbbVie, Biogen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceuticals, Eli Lilly and Company, Medac, MSD, NORDIC Pharma, Novartis, Pfizer Inc., Roche, Sanofi-Aventis, SOBI, UCB, Grant/research support from: AbbVie, Eli Lilly and Company, MSD, Pfizer Inc
Collapse
|
12
|
Liu F, Chu HX, Han JS, Sun X, Chen J, Qiu XL, Zheng XH, Jia B, Zhao JJ. Inhibitory effect of the Notch pathway-inhibitor DAPT on invasion and metastasis of tongue cancer via lncRNA-KAT14 regulation. Eur Rev Med Pharmacol Sci 2020; 24:189-199. [PMID: 31957832 DOI: 10.26355/eurrev_202001_19911] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE We aimed to identify a reliable biomarker for tongue squamous cell carcinoma (TSCC), the most common oral cancer with no established biomarkers, to predict prognosis and to select the optimal treatment. MATERIALS AND METHODS To investigate whether DAPT exhibited antitumor functions, CAL-27 and SCC-9 cells were treated with DAPT (5 µM or 10 µM) for different times. Further, qRT-PCR was used to determine the mRNA expression levels of lncRNA-KAT14 after treatment with DAPT or si-KAT14 and both combined. Moreover, the treated cells were cultured for different times to investigate their antitumor function. The Wound-healing and Transwell assay were carried out to evaluate the migration and invasion viability of cancer cells, respectively. Finally, the Western blots were performed to determine the expression of EMT-related proteins after transfection with si-KAT14 or treatment with DAPT to investigate the effects of DAPT on EMT-related proteins. RESULTS Proliferation was inhibited after treatment with DAPT, and the expression of lncRNA-KAT14 was upregulated. To investigate the correlation of DAPT and lncRNA-KAT14 on the metastasis and invasion in tongue cancer, the following cellular processes were assessed: proliferation, invasion, and migration ability. The Western blots were used to determine the expression of E-cadherin, N-cadherin, Vimentin, and Snail, showing that DAPT or lncRNA-KAT14 suppressed all these processes, inducing a decreased expression of N-cadherin, Vimentin, and Snail, and increased expression of E-cadherin, compared with the control group. Once transfection with si-KAT14 occurred, the evaluated cellular processes were enhanced, being this attenuated by the treatment with DAPT. CONCLUSIONS Our results suggest that DAPT suppresses invasion and metastasis of tongue cancer by regulating lncRNA-KAT14.
Collapse
Affiliation(s)
- F Liu
- Department of Oral Surgery, Stomatological Hospital, Southern Medical University, Guangzhou, China.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Zhang Y, Yu S, Ying X, Jia B, Liu L, Liu J, Kong L, Pei Z, Ma H. iTRAQ-based quantitative proteomics analysis reveals inhibitory mechanismsof the antimicrobial peptide MDAP-2 against Salmonella gallinarum. Pol J Vet Sci 2020; 23:405-414. [PMID: 33006863 DOI: 10.24425/pjvs.2020.134685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
MDAP-2 is a new AMP with high inhibitory activity on Salmonella gallinarum, which may be developed as an antimicrobial agent in the agricultural industry and food preservation. To investigate the underlying the action mechanism of MDAP-2 on Salmonella gallinarum, impacts of MDAP-2 on the growth curve and bacterial morphology of Salmonella gallinarum were studied. iTRAQ-based proteomics analysis was also performed on proteins extracted from treated and untreated Salmonella gallinarum cells. The differentially expressed proteins were then analyzed using the KEGG and GO databases. Finally, the function of some differentially expressed proteins was verified. The results showed that 150 proteins (41 up-regulated and 109 down-regulated) were found differentially expressed (fold > 1.8, p⟨0.05). The results indi- cate that MDAP-2 kills Salmonella gallinarum mainly through two mechanisms: (i) direct inhibi- tion of cell wall/ membrane/ envelope biogenesis, energy production/ conversion, carbohydrate transport/ metabolism, and DNA transcription/ translation through regulation of special protein levels; (ii) indirect effects on the same pathway through the accumulation of Reactive oxygen species (O2 ▪-, H2O2 and OH▪-).
Collapse
Affiliation(s)
- Y Zhang
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - S Yu
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - X Ying
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - B Jia
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - L Liu
- Jilin Medical University, Jilin Street No. 5, Jilin 132013, PR China
| | - J Liu
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - L Kong
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - Z Pei
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| | - H Ma
- College of Animal Science and Technology, Jilin Agricultural University, Xincheng Street No. 2888, Changchun 130118, PR China
| |
Collapse
|
14
|
Yuan F, Zhao ZT, Jia B, Wang YP, Lei W. TSN inhibits cell proliferation, migration, invasion, and EMT through regulating miR-874/HMGB2/β-catenin pathway in gastric cancer. Neoplasma 2020; 67:1012-1021. [PMID: 32484696 DOI: 10.4149/neo_2020_190919n931] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 01/07/2020] [Indexed: 11/08/2022]
Abstract
Gastric cancer (GC) is the second leading cause of cancer-associated deaths worldwide. Tanshinone IIA (TSN) is the pure extract from the root of red-rooted salvia and has been reported to inhibit the progression of GC cells. In this study, we investigated the microRNA (miRNA) mediated gene repression mechanism in TSN-administrated GC condition. The cell viability of GC was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. Cell migration and invasion were detected by transwell assays. The expression levels of epithelial-mesenchymal transition (EMT)-associated proteins (N-cadherin, vimentin, E-cadherin), High-mobility group box proteins 2 (HMGB2), β-catenin pathway-related proteins (β-catenin, c-myc, cyclin D1) were detected by western blot analysis in TSN/GC. The expression patterns of miR-874 and HMGB2 in GC were determined by quantitative real-time polymerase chain reaction (qRT-PCR). The potential miR-874-targeted HMGB2 was searched via bioinformatics methods and identified by dual-luciferase reporter assays, RNA immunoprecipitation (RIP) assays, and RNA pull-down assays. Xenograft tumor model was used to evaluate biological function in vivo. TSN limited the proliferation, migration, invasion, EMT progression in GC, and these results could be inverted by the silencing of miR-874. Moreover, the putative binding sites between miR-874 and HMGB2 were predicted by starBase software online. Meanwhile, enforced expression of HMGB2, negatively correlated with that of miR-874, reversed the positive effects of TSN administration on cells. Mechanically, TSN restrained the GC progression by miR-874/HMGB2/β-catenin signaling in vitro. Additionally, in vivo experiments confirmed that TSN inhibited the GC progression as well. TSN restrained the GC progression by regulating miR-874/HMGB2/β-catenin pathways in vitro and in vivo.
Collapse
Affiliation(s)
- F Yuan
- Department of Digestive Endoscopy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Z T Zhao
- Department of Special Inspection, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - B Jia
- Department of Digestive Endoscopy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Y P Wang
- Department of Digestive Endoscopy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - W Lei
- Chinese Medicine Department, Linyi People's Hospital, Linyi, China
| |
Collapse
|
15
|
Smolen JS, Xie L, Jia B, Taylor PC, Burmester GR, Tanaka Y, Elias A, Cardoso A, Ortmann R, Walls C, Dougados M. SAT0152 EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Baricitinib (Bari) is an oral, selective and reversible Janus kinase 1 and 2 inhibitor approved for the treatment of adults with active RA. In addition to long-term safety which has been disclosed previously with data up to 7 years [1], an important clinical consideration is whether treatment efficacy can be maintained over the long term.Objectives:To evaluate the long-term efficacy of once-daily Bari 4 mg in patients with active rheumatoid arthritis (RA) who were either naïve to or who had inadequate response (IR) to methotrexate (MTX)Methods:Post hoc analyses of data from two phase 3 studies, RA-BEGIN (MTX-naïve) and RA-BEAM (MTX-IR) for 52 weeks, and one long-term extension (LTE) study (RA-BEYOND) for an additional 96 weeks were conducted (148 weeks in total). At week 52, MTX-naïve patients initially treated with MTX monotherapy, Bari 4 mg monotherapy, or Bari 4 mg +MTX in RA-BEGIN were switched to open-label Bari 4 mg monotherapy for treatment in the LTE. Similarly, at week 52, MTX-IR patients initially treated with Bari 4 mg [+ background MTX noted as (+MTX) for RA-BEAM] or adalimumab (ADA) (+MTX) in RA-BEAM were switched to open-label Bari 4 mg (+MTX) for treatment in the LTE. Patients who received placebo (+MTX) were switched to open-label Bari 4 mg (+MTX) at week 24. The analyses of efficacy (SDAI) and physical function (HAQ-DI) were conducted on all patients who were randomized into the RA-BEGIN and RA-BEAM studies and had received ≥1 dose of study drug after randomization (mITT population). The proportion of patients who reached low disease activity (LDA), as measured by SDAI ≤11, was evaluated along with change from baseline in HAQ-DI. The non-responder imputation (NRI) method was used for the categorical analysis.Results:By week 24 in RA-BEGIN (N=584), 62% of patients treated with Bari 4 mg monotherapy or Bari 4 mg +MTX achieved SDAI LDA in comparison to 40% of pts in the MTX monotherapy group; response rates seen at week 24 in the Bari treatment groups were maintained through week 148 (Fig 1A). Similarly, by week 24 in RA-BEAM (N=1,305), 52% of patients treated with Bari 4 mg (+MTX) and 50% of patients treated with ADA (+MTX) achieved a SDAI LDA in comparison to 26% of patients from the PBO (+MTX) group. The response rate seen at week 24 with Bari 4 mg and ADA were maintained through week 148, even after patients switched from ADA to Bari 4 mg at week 52 (Fig 1B). Similar improvement and maintenance patterns in physical function measured by HAQ-DI were demonstrated. The overall discontinuation rate across treatment groups from RA-BEGIN (19.5%) and RA-BEAM (14.2%) have been published. In the LTE, the discontinuation rate from Bari treatment was 13.7% for patients originating from RA-BEGIN (1.1% due to lack of efficacy, 6.4% due to safety) and 12.6% for patients originating from RA-BEAM (1.8% due to lack of efficacy, 5.9% due to safety).Figure 1.Proportion of patients achieving SDAI ≤11 in the NRI analysis†In RA-BEGIN, rescue to Bari 4 mg + MTX was offered at week 24.‡In RA-BEAM, rescue to Bari 4 mg (+ MTX) was offered at week 16. At week 24, all PBO + MTX patients were switched to Bari 4 mg + MTX.§Upon entering RA-BEYOND at week 52, MTX and ADA patients were switched to Bari 4 mg.Conclusion:Long-term treatment with Bari 4 mg demonstrated the maintenance of clinically-relevant outcomes for up to 3 years. Low discontinuation rates during the LTE indicated that Bari 4 mg treatment was well-tolerated.References:[1]Genovese et al.Annals of the Rheumatic Diseases. 2019;78:308-309.Disclosure of Interests: :Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Li Xie Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Bochao Jia Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter C. Taylor Grant/research support from: Celgene, Eli Lilly and Company, Galapagos, and Gilead, Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Roche, and UCB, Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Yoshiya Tanaka Grant/research support from: Asahi-kasei, Astellas, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, Pfizer, and Ono, Consultant of: Abbvie, Astellas, Bristol-Myers Squibb, Eli Lilly, Pfizer, Speakers bureau: Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, AbbVie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Sanofi, UCB, and Teijin, Ayesha Elias Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Anabela Cardoso Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Robert Ortmann Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Chad Walls Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma
Collapse
|
16
|
Wu X, Zhou H, Wu X, Huang W, Jia B. Strategies for qualified triage stations and fever clinics during the outbreak of COVID-2019 in the county hospitals of Western Chongqing. J Hosp Infect 2020; 105:128-129. [PMID: 32205161 PMCID: PMC7118631 DOI: 10.1016/j.jhin.2020.03.021] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 03/16/2020] [Indexed: 12/17/2022]
Affiliation(s)
- X Wu
- Key Laboratory of Infectious and Parasitic Diseases, Infectious Disease Department, Infection Control Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - H Zhou
- Key Laboratory of Infectious and Parasitic Diseases, Infectious Disease Department, Infection Control Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - X Wu
- Infection Control Department, Yongchuan Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - W Huang
- Key Laboratory of Infectious and Parasitic Diseases, Infectious Disease Department, Infection Control Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - B Jia
- Key Laboratory of Infectious and Parasitic Diseases, Infectious Disease Department, Infection Control Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
| |
Collapse
|
17
|
Jia B, Wang W, Ni X, Chu X, Yoon S, Lawrence K. Detection of mycotoxins and toxigenic fungi in cereal grains using vibrational spectroscopic techniques: a review. WORLD MYCOTOXIN J 2020. [DOI: 10.3920/wmj2019.2510] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Nutrition-rich cereal grains and oil seeds are the major sources of food and feed for human and livestock, respectively. Infected by fungi and contaminated with mycotoxins are serious problems worldwide for cereals and oil seeds before and after harvest. The growth and development activities of fungi consume seed nutrients and destroy seed structures, leading to dramatic declines of crop yield and quality. In addition, the toxic secondary metabolites produced by these fungi pose a well-known threat to both human and animals. The existence of fungi and mycotoxins has been a redoubtable problem worldwide for decades but tends to be a severe food safety issue in developing countries and regions, such as China and Africa. Detection of fungal infection at an early stage and of mycotoxin contaminants, even at a small amount, is of great significance to prevent harmful toxins from entering the food supply chains worldwide. This review focuses on the recent advancements in utilising infrared spectroscopy, Raman spectroscopy, and hyperspectral imaging to detect fungal infections and mycotoxin contaminants in cereals and oil seeds worldwide, with an emphasis on recent progress in China. Brief introduction of principles, and corresponding shortcomings, as well as latest advances of each technique, are also being presented herein.
Collapse
Affiliation(s)
- B. Jia
- Beijing Key Laboratory of Optimized Design for modern Agricultural Equipment, College of Engineering, China Agriculture University, No. 17 Tsinghua East Road, Beijing, 100083, China P.R
| | - W. Wang
- Beijing Key Laboratory of Optimized Design for modern Agricultural Equipment, College of Engineering, China Agriculture University, No. 17 Tsinghua East Road, Beijing, 100083, China P.R
| | - X.Z. Ni
- Crop Genetics and Breeding Research Unit, USDA-ARS, 2747 Davis Road, Tifton, GA 31793, USA
| | - X. Chu
- College of Mechanical and Electrical Engineering, Zhongkai University of Agriculture and Engineering, Guangzhou 510225, China P.R
| | - S.C. Yoon
- Quality and Safety Assessment Research Unit, USDA-ARS, Athens, GA 30605, USA
| | - K.C. Lawrence
- Quality and Safety Assessment Research Unit, USDA-ARS, Athens, GA 30605, USA
| |
Collapse
|
18
|
Ma YH, Wu J, Jia B, Xue JX, Wang TL. [Continuous fascia iliaca compartment block combined with oral analgesics for pre-operative pain control in elderly hip fracture patients]. Zhonghua Yi Xue Za Zhi 2018; 98:723-727. [PMID: 29562394 DOI: 10.3760/cma.j.issn.0376-2491.2018.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: The purpose of this study was to assess the efficacy of ultrasound-guided continuous fascia iliaca compartment block combined with oral analgesics for pre-operative pain control in elderly patients with hip fracture. Methods: One hundred and sixteen patients with hip fractures in Xuan Wu Hospital of Capital Medical University during Dec. 2015 to Dec. 2016 were included. These patients were randomized into 2 groups: control group (group C) (receiving the traditional analgesia: tramadol 50 mg and paracetamol 500 mg tid, po from admission to surgery), study group (group S) (receiving ultrasound-guided continuous fascia iliaca compartment block combined with oral analgesics for pre-operative pain control from admission to surgery). Pain relief or pain intensity was assessed preoperatively at before administration of analgesia (T0), 1 h after administration of analgesia (T1), the second day after admission(T2), in the morning of surgery day (before surgery) (T3) using a visual analog scale. The satisfaction score with the analgesic regimen preoperatively was recorded. The amount of rescue analgesia, occurrence of adverse events (nausea, vomiting, respiratory depression, over sedation) and continuous fascia iliaca compartment block complications were also collected. Results: Pain scores (VAS) at passive movement of group S were significantly lower at T1 (32±8), T2 (32±8) and T3 (34±7) than that at T0 (73±12) (all P<0.05). VAS at rest of group S were significantly lower than those of group C at T3 (t=3.488, P<0.05). VAS at passive movement of group S were significantly lower than those of group C at T1,T2,T3 (P<0.05). The satisfaction score with the analgesic regimen was greater in group S (74±10) than that in group C (46±11) (t=-14.209, P<0.05). The incidence of rescue analgesia was lower in group S (0) than in group C (17.2%) (χ2=5.472, P<0.05). The occurrence of nausea and vomiting was 6.9% and 1.7% in group S, which were lower than that in group C (22.4%, 12.1%) (χ2=6.779, 2.416, all P<0.05). There were no obvious complications of continuous fascia iliaca compartment block in group S. Conclusion: Ultrasound guided continuous fascia iliaca compartment block combined with oral analgesics preoperatively is an effective way of providing analgesia for elderly with hip fracture, which can improve the patient's comfort and satisfaction.
Collapse
Affiliation(s)
- Y H Ma
- Department of Anesthesiology, Xuan Wu Hospital of Capital Medical University, Beijing 100053, China
| | | | | | | | | |
Collapse
|
19
|
Liu Q, Feng L, Qu B, Ma L, Jia B, Dai G, Du X, Liu H, Gao Y, Wang Y, Chen J. Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.06.180] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Wang J, Xia J, Zhang R, Yan X, Yang Y, Zhao X, Chang H, Wang G, Chen G, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B. J Viral Hepat 2018; 25:1151-1160. [PMID: 29741221 DOI: 10.1111/jvh.12925] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 04/20/2018] [Indexed: 12/14/2022]
Abstract
Identifying the degree of liver inflammation is critical for therapeutic judgement of patients with chronic hepatitis B (CHB). However, we lack indexes which can accurately predict significant liver inflammation in patients with CHB. This study aimed to develop a simple predictive index for liver inflammation in CHB using routine clinical parameters. A total of 519 patients with CHB who underwent liver biopsy were enrolled and randomly divided into training (n = 346) and validation cohorts (n = 173). Based on routine clinical parameters, gamma-glutamyl transpeptidase (GGT; P = 0.031) and platelets (PLT; P < 0.001) were identified as independent predictors of significant inflammation by multivariable analysis in the training cohort. Accordingly, the GGT to PLT ratio (GPR) was developed to amplify the opposing effects for predicting liver inflammation. In the training cohort, the AUCs of GPR in predicting significant inflammation were 0.791 (95% CI: 0.742-0.839), 0.783 (95% CI: 0.717-0.849) and 0.791 (95% CI: 0.716-0.867) in the entire patients with CHB, HBeAg-positive CHB patients and HBeAg-negative CHB patients, respectively. The diagnostic performance of GPR for significant inflammation was significantly superior to that of alanine aminotransferase (ALT), aspartate transaminase (AST) and GGT in all patients with CHB and HBeAg-positive CHB patients, but was comparable with ALT, AST and GGT in HBeAg-negative CHB patients. In the validation cohort, the diagnostic performance of GPR in assessing significant liver inflammation was also superior to other indexes in all patients with CHB and HBeAg-positive CHB patients, but was comparable with GGT in HBeAg-negative CHB patients. Thus, GPR can be a novel and simple index for predicting significant liver inflammation in CHB, especially for HBeAg-positive CHB.
Collapse
Affiliation(s)
- J Wang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.,Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - J Xia
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - R Zhang
- Department of Hepatology, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, China
| | - X Yan
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Y Yang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - X Zhao
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China
| | - H Chang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China
| | - G Wang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - G Chen
- Department of Infectious Diseases, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China
| | - Y Liu
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Y Chen
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - B Jia
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Z Zhang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - W Ding
- Department of Hepatology, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, China
| | - R Huang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - C Wu
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.,Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China
| |
Collapse
|
21
|
Abstract
PURPOSE The aim of this study was to analyze the blood glucose (BG) variations in cancer patients during chemotherapy according to tumor types and chemotherapeutic regimens. MATERIALS AND METHODS Patients were examined from the Department of Medical Oncology of Cancer Hospital and Institute, Chinese Academy Medical Sciences from January 2012 to December 2014. The patients' ages, genders, body mass index, associated disease history, and corresponding BG values were recorded. RESULTS Among these 2029 patients, 331 (16.3%) patients encountered high BG during chemotherapy except diabetic patients. Of these patients, 208 (62.8%) were males, and 123 (37.2%) were females, with age ranged from 17 to 84 years. The 331 cases included 23 tumor types and 77 regimens. Totally, BG values increased up to 7.4 ± 1.3 mmol/L during chemotherapy. CONCLUSIONS No previous studies in the literature have examined systematically so numerous cases of hyperglycemia during chemotherapy. This study has pointed out possible high-risk chemotherapeutic regimens and tumor types, which should be paid attention to prevent the occurrence of hyperglycemia.
Collapse
Affiliation(s)
- J Yang
- Department of Pharmacy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - B Jia
- Department of Pharmacy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Y Qiao
- Department of Pharmacy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - W Chen
- Department of Pharmacy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - X Qi
- Center of Information Management, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| |
Collapse
|
22
|
Dong YT, Tian FC, Jia B, Zu B, Wang XY. [Influence of setting time on bond strength of different bioactive pulp capping materials with dental adhesive]. Beijing Da Xue Xue Bao Yi Xue Ban 2018; 50:58-62. [PMID: 29483723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To investigate influence of setting time on bond strength of different bioactive pulp capping materials with self-etch or etch-and-rinse adhesive. METHODS Sixty specimens were prepared for each of the three tested capping materials, namely mineral trioxide aggregate (MTA), iRoot BP Plus (BP) and iRoot FS (FS). Specimens of each material were divided into three groups and bonded at three setting time points of the materials respectively: initial setting time (4 h for MTA, 2 h for BP and 20 min for FS), 24 h after application and 7 d after application. The specimen surfaces of each group were treated with self-etch mode or etch-and-rinse mode of one universal adhesive (Single Bond Universal, SBU) (n=10). The bonding area was restricted to a round area with 3 mm diameter, on which composite cylinders were build up with flowable composite and light cured completely. The shear bond strength was tested immediately with a shear strength tester and fracture mode was observed under stereo microscope and recorded. The mean shear bond strength for each group was analyzed with SPSS 19.0 software ANOVA method. The surface morphology of each material was observed after setting and acid treatment under scanning electron microscope. RESULTS There was no significant difference among the three tested materials at either initial setting point or 7 d after application (P<0.05). The bond strength of MTA was significantly higher than those of BP and FS 24 h after application in both bonding modes (P<0.05). For all the three tested materials, shear bond strength was significantly higher for complete setting group than for initial setting group of the same material (P<0.05). Under scanning electron microscope, the characteristic crystal patterns could be observed on the three bioactive materials surfaces after complete setting, the size of which was bigger for MTA than for BP and FS. These features were lost to some extent after self-etch primer application or phosphoric acid etching. CONCLUSION Based on the present results, adequate bond strength can be obtained for FS at initial setting time, which is comparable with BP and MTA. This implies that clinically composite restoration can be placed over bioactive direct capping materials after shortened initial setting process in one visit.
Collapse
Affiliation(s)
- Y T Dong
- Department of VIP Dental Service, Peking Chongwen Hospital of Stomatology, Beijing 100062, China
| | - F C Tian
- Department of Cariology and Endodontology, Peking University School and Hospital of Stomatology & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
| | - B Jia
- Department of VIP Dental Service, Peking Chongwen Hospital of Stomatology, Beijing 100062, China
| | - B Zu
- Department of VIP Dental Service, Peking Chongwen Hospital of Stomatology, Beijing 100062, China
| | - X Y Wang
- Department of Cariology and Endodontology, Peking University School and Hospital of Stomatology & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
| |
Collapse
|
23
|
Gao EJ, Meng B, Su JQ, Peng TT, Qi ZZ, Jia B, Feng YH, Zhu MC. Structure, DNA bonding, and biological activity of a novel Pb(II) complex of 1,1-bis(5-(pyrazin-2-yl)-1,2,4-triazol-3-yl) methane. J STRUCT CHEM+ 2018. [DOI: 10.1134/s0022476617080121] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
24
|
|
25
|
Chi K, Protheroe A, Rodriguez Antolin A, Facchini G, Suttmann H, Matsubara N, Ye ZQ, Keam B, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd M, Fizazi K. Benefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx370] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Zhao QM, Liu F, Wu L, Ye M, Jia B, Ma XJ, Huang GY. [Assessment of undiagnosed critical congenital heart disease before discharge from the maternity hospital]. Zhonghua Er Ke Za Zhi 2017; 55:260-266. [PMID: 28441821 DOI: 10.3760/cma.j.issn.0578-1310.2017.04.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Objective: Undiagnosed critical congenital heart disease (CCHD) was assessed before discharge from maternity hospital.Basic information was provided for screening CCHD in the early neonatal stage.Chi-squared test was used for comparison of categorical variables(detection rate of different types of CCHD). Method: A retrospective cohort study was conducted in neonates with CCHD who were admitted to Children's Hospital of Fudan University between 1 January 2012 and 31 December 2015. For comparing with the previously reported undiagnosed rate of CCHD at discharge, CCHD was defined as all duct dependent congenital heart disease (DDCHD) and any cyanotic CHD that required early surgery. Result: A total of 1 036 infants with CCHD were included. The prenatal detection rate of CCHD was 14.04%(122/869). As a whole, 52.51% (544/1 036) of CCHD cases were undiagnosed at discharge, and 14.09%(146/1 036)were still missed after 6-week examination. The diagnoses most likely to be unrecognized at discharge included critical coarctation of the aorta (COA) (75.00%), total anomalous pulmonary venous connection (61.54%), pulmonary atresia (PA) with ventricle septal defect (VSD) (61.45%), single ventricle (SV) (60.10%) and critical aortic stenosis (52.94%). Among newborns diagnosed prior to discharge, 54.88% (270/492) due to symptom or prenatal ultrasonographic diagnosis, 45.12% (222/492) due to abnormal findings in routine examination. Among asymptomatic CCHD cases without prenatal diagnosis, 71.02% (544/766) were undiagnosed and the most common delayed diagnosis was SV (82.78%), interrupted aortic arch (81.82%), transposition of the great arteries with intact ventricular septum (79.63%), PA/VSD (79.07%), and critical COA (78.57%). Newborns with DDC were more likely to develop symptoms within the first few days after birth, in comparison with non-DDC cases. However, their detection rates were close to each other. Conclusion: The rate of misdiagnosis of CCHD before discharge from maternity hospitals is high in China, indicates the importance of implementation of CCHD screening in Chinese maternity hospitals, so as to give timely diagnosis and proper treatment.
Collapse
Affiliation(s)
- Q M Zhao
- Pediatric Heart Center, Children's Hospital of Fudan University, Shanghai 201102, China
| | | | | | | | | | | | | |
Collapse
|
27
|
Zhang H, He G, Kong Y, Chen Y, Wang B, Sun X, Jia B, Xie X, Wang X, Chen D, Wei L, Zhang M, Zeng H, Chen H. Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver. Clin Exp Immunol 2017; 188:96-108. [PMID: 28019655 DOI: 10.1111/cei.12917] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/2016] [Indexed: 12/13/2022] Open
Abstract
Regulating mechanisms underlying hepatic myeloid-derived suppressor cell (MDSC) accumulation remain to be described. Here, we provide evidence for the involvement of tumour-activated liver stromal cells in the process of hepatic MDSCs migration and accumulation. Our data showed an elevated frequency of MDSCs in the liver of tumour-bearing mice. Moreover, tumour-activated liver stromal cells promote MDSC migration into the liver site. Further investigation indicated higher levels of cytokine and chemokine expression in liver stromal cells after exposure to the tumour-conditioned supernatant. Notably, the expression levels of proinflammatory factors, mainly including macrophage colony stimulating factor (M-CSF), transforming growth factor-β (TGF-β), monocyte chemotactic protein-1 (MCP-1) and stromal-derived factor-1 (SDF-1), increased after treatment with tumour-conditioned supernatant, and blockade of MCP-1 or SDF-1 decreased the proportion of tumour infiltrated MDSCs in mice co-transplanted with liver stromal cells and tumour cells, but not in mice with only tumour cells injection. These findings demonstrate that tumour-activated liver stromal cells produce higher levels of chemokines and cytokines, which may contribute to MDSC accumulation into the liver site in patients with liver cancer.
Collapse
Affiliation(s)
- H Zhang
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China.,Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - G He
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| | - Y Kong
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - Y Chen
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| | - B Wang
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - X Sun
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| | - B Jia
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - X Xie
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| | - X Wang
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| | - D Chen
- Institute of Immunology, Tsinghua University School of Medicine, Beijing, China
| | - L Wei
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| | - M Zhang
- Institute of Immunology, Tsinghua University School of Medicine, Beijing, China
| | - H Zeng
- Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.,Beijing Key Laboratory of Emerging Infectious Diseases, Beijing, China
| | - H Chen
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.,Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, China
| |
Collapse
|
28
|
Huang R, Yan X, Jia B, Wang G, Liu Y, Wu C. Letter: need to re-evaluate non-invasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther 2017; 45:574-575. [PMID: 28074515 DOI: 10.1111/apt.13890] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- R Huang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
| | - X Yan
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
| | - B Jia
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
| | - G Wang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Y Liu
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
| | - C Wu
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China
| |
Collapse
|
29
|
Huang R, Wang G, Liu Y, Jia B, Wu C. Letter: is body-mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B? Aliment Pharmacol Ther 2017; 45:482. [PMID: 28043095 DOI: 10.1111/apt.13885] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- R Huang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - G Wang
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - Y Liu
- Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - B Jia
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - C Wu
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| |
Collapse
|
30
|
He J, Yang J, Jia B, Yan J. Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer. Niger J Clin Pract 2017; 20:1422-1427. [DOI: 10.4103/njcp.njcp_444_16] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, Zhang XJ, Zhang CX, Ji P, Xie Y, Kang M, Wang CQ, Wang AM, Xu YH, Shen JL, Sun ZY, Chen ZJ, Ni YX, Sun JY, Chu YZ, Tian SF, Hu ZD, Li J, Yu YS, Lin J, Shan B, Du Y, Han Y, Guo S, Wei LH, Wu L, Zhang H, Kong J, Hu YJ, Ai XM, Zhuo C, Su DH, Yang Q, Jia B, Huang W. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016; 22 Suppl 1:S9-14. [PMID: 27000156 DOI: 10.1016/j.cmi.2016.01.001] [Citation(s) in RCA: 238] [Impact Index Per Article: 29.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2015] [Revised: 01/07/2016] [Accepted: 01/07/2016] [Indexed: 02/05/2023]
Abstract
With the aim of gathering temporal trends on bacterial epidemiology and resistance from multiple laboratories in China, the CHINET surveillance system was organized in 2005. Antimicrobial susceptibility testing was carried out according to a unified protocol using the Kirby-Bauer method or automated systems. Results were analyzed according to Clinical and Laboratory Standards Institute (CLSI) 2014 definitions. Between 2005 and 2014, the number of bacterial isolates ranged between 22,774 and 84,572 annually. Rates of extended-spectrum β-lactamase production among Escherichia coli isolates were stable, between 51.7 and 55.8%. Resistance of E. coli and Klebsiella pneumoniae to amikacin, ciprofloxacin, piperacillin/tazobactam and cefoperazone/sulbactam decreased with time. Carbapenem resistance among K. pneumoniae isolates increased from 2.4 to 13.4%. Resistance of Pseudomonas aeruginosa strains against all of antimicrobial agents tested including imipenem and meropenem decreased with time. On the contrary, resistance of Acinetobacter baumannii strains to carbapenems increased from 31 to 66.7%. A marked decrease of methicillin resistance from 69% in 2005 to 44.6% in 2014 was observed for Staphylococcus aureus. Carbapenem resistance rates in K. pneumoniae and A. baumannii in China are high. Our results indicate the importance of bacterial surveillance studies.
Collapse
Affiliation(s)
- F-P Hu
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
| | - Y Guo
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
| | - D-M Zhu
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China
| | - F Wang
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
| | - X-F Jiang
- Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China
| | - Y-C Xu
- Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China
| | - X-J Zhang
- Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China
| | - C-X Zhang
- Laboratory Medicine, The First Teaching Hospital of Xinjiang Medical University, Xinjiang, China
| | - P Ji
- Laboratory Medicine, The First Teaching Hospital of Xinjiang Medical University, Xinjiang, China
| | - Y Xie
- Laboratory Medicine, West China Hospital, Sichuan University, Sichuan, China
| | - M Kang
- Laboratory Medicine, West China Hospital, Sichuan University, Sichuan, China
| | - C-Q Wang
- Laboratory Medicine, Children's Hospital of Fudan University, Shanghai, China
| | - A-M Wang
- Laboratory Medicine, Children's Hospital of Fudan University, Shanghai, China
| | - Y-H Xu
- Laboratory Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui, China
| | - J-L Shen
- Laboratory Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui, China
| | - Z-Y Sun
- Laboratory Medicine, Tongji Hospital of Huazhong University of Science and Techonology, Hubei, China
| | - Z-J Chen
- Laboratory Medicine, Tongji Hospital of Huazhong University of Science and Techonology, Hubei, China
| | - Y-X Ni
- Laboratory Medicine, Ruijin Hospital of Shanghai Jiaotong University, Shanghai, China
| | - J-Y Sun
- Laboratory Medicine, Ruijin Hospital of Shanghai Jiaotong University, Shanghai, China
| | - Y-Z Chu
- Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China
| | - S-F Tian
- Laboratory Medicine, The First Hospital of China Medical University, Shenyang, China
| | - Z-D Hu
- Laboratory Medicine, General Hospital of Tianjin Medical University, Tianjin, China
| | - J Li
- Laboratory Medicine, General Hospital of Tianjin Medical University, Tianjin, China
| | - Y-S Yu
- Laboratory Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Zhejiang, China
| | - J Lin
- Laboratory Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Zhejiang, China
| | - B Shan
- Laboratory Medicine, The First Affiliated Hospital of Yunnan Medical University, Yunnan, China
| | - Y Du
- Laboratory Medicine, The First Affiliated Hospital of Yunnan Medical University, Yunnan, China
| | - Y Han
- Laboratory Medicine, The First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China
| | - S Guo
- Laboratory Medicine, The First Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China
| | - L-H Wei
- Laboratory Medicine, Gansu Province Hospital, Gansu, China
| | - L Wu
- Laboratory Medicine, Gansu Province Hospital, Gansu, China
| | - H Zhang
- Laboratory Medicine, Children's Hospital of Shanghai, Shanghai, China
| | - J Kong
- Laboratory Medicine, Children's Hospital of Shanghai, Shanghai, China
| | - Y-J Hu
- Laboratory Medicine, Beijing Hospital, Beijing, China
| | - X-M Ai
- Laboratory Medicine, Beijing Hospital, Beijing, China
| | - C Zhuo
- Laboratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - D-H Su
- Laboratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Q Yang
- Laboratory Medicine, The First Affiliated Hospital of Zhejiang University, Zhejiang, China
| | - B Jia
- Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - W Huang
- Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| |
Collapse
|
32
|
|
33
|
Jia L, Duan J, Deng B, Bai W, Liu M, Li D, Jia B. A logistic regression model based on tongue image information for prediction precancerous lesions and early stage esophageal cancer in China. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw385.06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Wang C, Wang J, Jia D, Li L, Jia B, Fan S, Song J, Hu X, Wang Y, Wang D. Anti-nociceptive effects of Paecilomyces hepiali via multiple pathways in mouse models. Genet Mol Res 2016; 15:gmr8996. [PMID: 27706666 DOI: 10.4238/gmr.15038996] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Paecilomyces hepiali (PH), a well-known medicinal fungus, has various pharmacological efficacies. In our study, the antinociceptive effects of PH and underlying mechanisms were evaluated using various mouse models. An acetic acid-induced writhing test, hot plate test, and formalin test were employed to evaluate the antinociceptive activities of PH. The levels of neuronal nitric oxide synthase (nNOS) in the hypothalamus and monoamine neurotransmitters in the serum and hypothalamus of experimental mice were examined. Additionally, hot plate tests using mice pretreated with various antagonists were used to determine the mechanisms of PH-mediated antinociception. The PH-enhanced latency period of mice in the hot plate test was significantly blocked by pretreatment with atropine and glibenclamide. PH shortened the phase I and phase II reaction times of formalin-treated mice. Strongly reduced writhing and stretching induced by acetic acid were observed in PH-treated mice, indicating that PH mainly exerts antinociceptive activity on neurogenic pain. After thermal pain stimulation for 30 s, compared to control mice, 7-day PH-treated mice had lower nNOS and dopamine levels, and increased levels of serotonin in both the serum and hypothalamus. Collectively, our data showed that PH mediated antinociceptive activities via multiple pathways, including monoamines, nNOS/ATP-sensitive K+ channels, and M-type acetylcholine receptors.
Collapse
Affiliation(s)
- C Wang
- School of Life Sciences, Jilin University, Changchun, China
| | - J Wang
- School of Life Sciences, Jilin University, Changchun, China
| | - D Jia
- School of Life Sciences, Jilin University, Changchun, China
| | - L Li
- School of Life Sciences, Jilin University, Changchun, China
| | - B Jia
- School of Life Sciences, Jilin University, Changchun, China
| | - S Fan
- School of Life Sciences, Jilin University, Changchun, China
| | - J Song
- School of Life Sciences, Jilin University, Changchun, China
| | - X Hu
- Faculty of Clinical Medicine, Changchun Medical College, Changchun, China
| | - Y Wang
- School of Life Sciences, Jilin University, Changchun, China
| | - D Wang
- School of Life Sciences, Jilin University, Changchun, China
| |
Collapse
|
35
|
Yan XG, Lu ZJ, Zheng JC, Zhang WW, Lu GP, Jia B. [Application of right jugular vessels to build extracorporeal membrane oxygenation for treating the critically ill children]. Zhonghua Er Ke Za Zhi 2016; 54:515-8. [PMID: 27412742 DOI: 10.3760/cma.j.issn.0578-1310.2016.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To summarize the experience in applying a technique of inserting a cannula through right internal jugular vein and common carotid artery to build extracorporeal membrane oxygenation (ECMO) for critically ill children. METHOD The data of critically ill patients received ECMO support through right internal jugular vein and common carotid artery between December 2011 and December 2015 from Children's Hospital of Fudan University were analyzed retrospectively.The data included diagnosis, age, body weight, time of cannula and ECMO running, complication and prognosis. RESULT In total 28 patients received ECMO support, 3 patients of post-cardiac surgery with transthoracic cannula were excluded.Twenty-five patients inserted cannula through neck vessels were enrolled, 15 boys and 10 girls, the median age was 1.8 years (range, 1 d-13 years), the median weight was 12.0 (2.8-50.0) kg.All the cannula sites were right internal jugular vein and right common carotid artery, before cannula use 5 patients had been inserted central vein tube and 3 patients with blood filter tube in right internal jugular vein, in one case cannula was applied during cardiopulmonary resuscitation.V-A ECMO had been built for all the cases successfully, the median operation time was (45±26) min.The pump flow was 80-150 ml/(kg·min), the median duration of ECMO support was 153(14-567) h. Sixteen (64%) patients weaned off ECMO successfully, 15(60%) survived to hospital discharge.About the complication of cannula, six patients developed cannula site bleeding, and two patients required re-fixation of cannula, one patient's external jugular vein had been hurt and sutured for bleeding. CONCLUSION Application of right jugular vessels to build ECMO is easy and safe for treating the sick children. The skill should be proficient to assure ECMO run and reduce the complications.
Collapse
Affiliation(s)
- X G Yan
- Department of Cardiothoracic Surgery, Children's Hospital of Fudan University, Shanghai 201102, China
| | | | | | | | | | | |
Collapse
|
36
|
Lamba V, Jia B, Liang F. STAT5A and STAT5B have opposite correlations with drug response gene expression. Biochem Biophys Res Commun 2016; 479:117-124. [PMID: 27264955 DOI: 10.1016/j.bbrc.2016.06.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 06/02/2016] [Indexed: 12/23/2022]
Abstract
INTRODUCTION STAT5A and STAT5B are important transcription factors that play a key role in regulation of several important physiological processes including proliferation, survival, mediation of responses to cytokines and in regulating gender differences in drug response genes such as the hepatic cytochrome P450s (CYPs) that are responsible for a large majority of drug metabolism reactions in the human body. STAT5A and STAT5b have a high degree of sequence homology and have been reported to have largely similar functions. Recent studies have, however, indicated that they can also often have distinct and unique roles in regulating gene expression. OBJECTIVE In this study, we evaluated the association of STAT5A and STAT5B mRNA expression levels with those of several key hepatic cytochrome P450s (CYPs) and hepatic transcription factors (TFs) and evaluated the potential roles of STAT5A and 5b in mediating gender differences in these CYPs and TFs. METHODS Expression profiling for major hepatic CYP isoforms and transcription factors was performed using RNA sequencing (RNA-seq) in 102 human liver samples (57 female, 45 male). Real time PCR gene expression data for selected CYPs and TFs was available on a subset of 50 human liver samples (25 female, 25 male) and was used to validate the RNA-seq findings. RESULTS While STAT5A demonstrated significant negative correlation with expression levels of multiple hepatic transcription factors (including NR1I2 and HNF4A) and DMEs such as CYP3A4 and CYP2C19, STAT5B expression was observed to demonstrate positive associations with several CYPs and TFs analyzed. As STAT5A and STAT5B have been shown to be important in regulation of gender differences in CYPs, we also analyzed STAT5A and 5b associations with CYPs and TFs separately in males and females and observed gender dependent differential associations of STATs with several CYPs and TFs. Results from the real time PCR validation largely supported our RNA-seq findings. CONCLUSIONS Using both RNA sequencing and real time PCR, we examined the association of STAT5A and STAT5B mRNA expression with CYP and TF gene expression. While STAT5A demonstrated significant negative correlations with expression levels of multiple hepatic TFs (including NR1I2 and HNF4α) and CYPs (eg. CYP3A4, CYP2C19), STAT5B expression was observed to demonstrate positive association with most of the CYPs/TFs analyzed suggesting that STAT5A and STAT5b have potentially different and distinct roles in regulating expression of hepatic drug response genes. Further studies are needed to elucidate the potential roles of STAT5A and 5b in regulation of CYPs/TFs and the potential implications of these findings.
Collapse
Affiliation(s)
- V Lamba
- Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States.
| | - B Jia
- Department of Biostatistics, University of Florida, Gainesville, FL 32611, United States
| | - F Liang
- Department of Biostatistics, University of Florida, Gainesville, FL 32611, United States
| |
Collapse
|
37
|
Zhang Y, Jia B, Gu M. Biomimetic and plasmonic hybrid light trapping for highly efficient ultrathin crystalline silicon solar cells. Opt Express 2016; 24:A506-A514. [PMID: 27136871 DOI: 10.1364/oe.24.00a506] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Designing effective light-trapping structures for the insufficiently absorbed long-wavelength light in ultrathin silicon solar cells represents a key challenge to achieve low cost and highly efficient solar cells. We propose a hybrid structure based on the biomimetic silicon moth-eye structure combined with Ag nanoparticles to achieve advanced light trapping in 2 μm thick crystalline silicon solar cells approaching the Yablonovitch limit. By synergistically using the Mie resonances of the silicon moth-eye structure and the plasmonic resonances of the Ag nanoparticles, the integrated absorption enhancement achieved across the usable solar spectrum is 69% compared with the cells with the conventional light trapping design. This is significantly larger than both the silicon moth-eye structure (58%) and Ag nanoparticle (41%) individual light trapping. The generated photocurrent in the 2 μm thick silicon layer is as large as 33.4 mA/cm2, which is equivalent to that generated by a 30 μm single-pass absorption in the silicon. The research paves the way for designing highly efficient light trapping structures in ultrathin silicon solar cells.
Collapse
|
38
|
Jia B, Xiao W, Wang TL. [Expression and mechanism of nitric oxide synthase in cerebral hyperperfusion rats]. Zhonghua Yi Xue Za Zhi 2016; 96:468-71. [PMID: 26875926 DOI: 10.3760/cma.j.issn.0376-2491.2016.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To explore the expression and mechanism of different nitric oxide synthase in cerebral hyperperfusion rats. METHODS Male Wistar rats were anesthetized and a ventral midline incision was made. The bilateral common carotid arteries were gently separated. Each artery was ligated with a 5-0 silk suture. Sham groups underwent the same operation without occlusion two weeks later, the ligature was loosened under a microscope to induce reperfusion. Phenylephrine was administered at concentration of 50 μg/ml via tail vein.After hyperperfusion, the expression of iNOS and eNOS in hippocampus , cortex and common carotid arteries of rats brain was observed by using Western blot of each group. RESULTS The expression of iNOS in differernt sites were increased significantly after reperfusion of 24 hours. The ratio of iNOS and β-actin in hippocampus in sham, BCAO, HP, HP 24 and HP 48 groups were 21.10±2.53, 24.37±2.30, 28.34±2.86, 43.76±2.58, 38.90±3.17, respectively. There was significant difference between HP 24 and other groups (F=13.03, all P<0.05). The ratio of iNOS and β-actin in cortex in each group were 12.98±2.31, 15.00±1.66, 14.71±1.48, 34.76±5.01, 32.60±5.73, respectively (F=8.42, all P<0.05). The ratio of iNOS and β-actin in common carotid arteries in each group were 7.30±2.55, 8.83±1.45, 4.76±0.71, 28.00±2.21, 26.29±3.33 (F=24.82, all P<0.05). While the levels of eNOS in that three sites presented no significant change(all P>0.05). CONCLUSIONS Hyperperfusion can induce iNOS ecpression in quantities in hippocamps, cortex and common carotid arteries. These levesl would last until 48 hours after reperfusion. This process suggests that iNOS is the possible mechanism of hyperperfusion.
Collapse
Affiliation(s)
- B Jia
- Department of Anesthesiology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
| | | | | |
Collapse
|
39
|
Wang J, Wang F, Liu Y, Xu J, Lin H, Jia B, Zuo W, Jiang Y, Hu L, Lin F. Multiple Linear Regression and Artificial Neural Network to Predict Blood Glucose in Overweight Patients. Exp Clin Endocrinol Diabetes 2016; 124:34-8. [PMID: 26797861 DOI: 10.1055/s-0035-1565175] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND Overweight individuals are at higher risk for developing type II diabetes than the general population. We conducted this study to analyze the correlation between blood glucose and biochemical parameters, and developed a blood glucose prediction model tailored to overweight patients. METHODS A total of 346 overweight Chinese people patients ages 18-81 years were involved in this study. Their levels of fasting glucose (fs-GLU), blood lipids, and hepatic and renal functions were measured and analyzed by multiple linear regression (MLR). Based the MLR results, we developed a back propagation artificial neural network (BP-ANN) model by selecting tansig as the transfer function of the hidden layers nodes, and purelin for the output layer nodes, with training goal of 0.5×10(-5). RESULTS There was significant correlation between fs-GLU with age, BMI, and blood biochemical indexes (P<0.05). The results of MLR analysis indicated that age, fasting alanine transaminase (fs-ALT), blood urea nitrogen (fs-BUN), total protein (fs-TP), uric acid (fs-BUN), and BMI are 6 independent variables related to fs-GLU. Based on these parameters, the BP-ANN model was performed well and reached high prediction accuracy when training 1 000 epoch (R=0.9987). CONCLUSIONS The level of fs-GLU was predictable using the proposed BP-ANN model based on 6 related parameters (age, fs-ALT, fs-BUN, fs-TP, fs-UA and BMI) in overweight patients.
Collapse
Affiliation(s)
- J Wang
- Department of Infection and Liver Diseases, Liver Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
| | - F Wang
- Beijing Hui-Long-Guan Hospital, Peking University, Beijing, China
| | - Y Liu
- Wenzhou Medical University, Wenzhou, China
| | - J Xu
- The Affiliated Wenling Hospital of Wenzhou Medial University, Wenling, China
| | - H Lin
- Wenzhou Medical University, Wenzhou, China
| | - B Jia
- Inner Mongolia Medical University, Hohhot, China
| | - W Zuo
- Ningbo Fourth Hospital, Xiangshan, China
| | - Y Jiang
- Ningbo Fourth Hospital, Xiangshan, China
| | - L Hu
- Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
| | - F Lin
- Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
| |
Collapse
|
40
|
Wu Q, Mao J, Wei C, Fu S, Law R, Ding L, Yu B, Jia B, Yang C. Hybrid BF–PSO and fuzzy support vector machine for diagnosis of fatigue status using EMG signal features. Neurocomputing 2016. [DOI: 10.1016/j.neucom.2015.06.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
41
|
Liu S, Song L, Cram DS, Xiong L, Wang K, Wu R, Liu J, Deng K, Jia B, Zhong M, Yang F. Traditional karyotyping vs copy number variation sequencing for detection of chromosomal abnormalities associated with spontaneous miscarriage. Ultrasound Obstet Gynecol 2015; 46:472-477. [PMID: 25767059 DOI: 10.1002/uog.14849] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2014] [Revised: 02/19/2015] [Accepted: 03/10/2015] [Indexed: 06/04/2023]
Abstract
OBJECTIVES To compare the performance of traditional G-banding karyotyping with that of copy number variation sequencing (CNV-Seq) for detection of chromosomal abnormalities associated with miscarriage. METHODS Products of conception (POC) were collected from spontaneous miscarriages. Chromosomal abnormalities were detected using high-resolution G-banding karyotyping and CNV sequencing. Quantitative fluorescent polymerase chain reaction analysis of maternal and POC DNA for short tandem repeat (STR) markers was used to both monitor maternal cell contamination and confirm the chromosomal status and sex of the miscarriage tissue. RESULTS A total of 64 samples of POC, comprising 16 with an abnormal and 48 with a normal karyotype, were selected and coded for analysis by CNV-Seq. CNV-Seq results were concordant for 14 (87.5%) of the 16 gross chromosomal abnormalities identified by karyotyping, including 11 autosomal trisomies and three sex chromosomal aneuploidies (45,X). Of the two discordant results, a 69,XXX polyploidy was missed by CNV-Seq, although supporting STR marker analysis confirmed the triploidy. In contrast, CNV-Seq identified a sample with 45,X karyotype as a 45,X/46,XY mosaic. In the remaining 48 samples of POC with a normal karyotype, CNV-Seq detected a 2.58-Mb 22q deletion associated with DiGeorge syndrome and nine different smaller CNVs of no apparent clinical significance. CONCLUSIONS CNV-Seq used in parallel with STR profiling is a reliable and accurate alternative to karyotyping for identifying chromosome copy number abnormalities associated with spontaneous miscarriage.
Collapse
Affiliation(s)
- S Liu
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - L Song
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - D S Cram
- Berry Genomics, Chaoyang District, Beijing, China
| | - L Xiong
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - K Wang
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - R Wu
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - J Liu
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Guangzhou, Guangdong, China
| | - K Deng
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - B Jia
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - M Zhong
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| | - F Yang
- Southern Medical University, Nanfang Hospital, Department of Obstetrics and Gynecology, Technology Center of Prenatal Diagnosis and Genetic Diseases Diagnosis, Guangzhou, Guangdong, China
| |
Collapse
|
42
|
Shi Y, Mo H, Hao X, Liu Y, Wang L, Hu X, Xu J, Yang S, Xing P, Shi Y, Jia B, Wang Y, Li J, Wang H, Wang Z, Sun Y. 3055 A prognostic model for platinum-doublet regimens as second-line chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31697-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Zhan X, Yu G, He N, Jia B, Zhou M, Wang C, Zhang J, Zhao G, Wang S, Liu Y, Yan J. Inorganic nitrogen wet deposition: Evidence from the North-South Transect of Eastern China. Environ Pollut 2015; 204:1-8. [PMID: 25898231 DOI: 10.1016/j.envpol.2015.03.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 03/06/2015] [Accepted: 03/08/2015] [Indexed: 06/04/2023]
Abstract
We examined the spatio-temporal variation of dissolved inorganic nitrogen (DIN) deposition in eight typical forest ecosystems of Eastern China for three consecutive years. DIN deposition exhibited an increasing gradient from north to south, with N-NH4(+) as the predominant contributor. DIN deposition in precipitation changed after interaction with the forest canopy, and serious ecological perturbations are expected in this region. DIN deposition presented seasonal fluctuations, which might be ascribed to agricultural activity, fossil-fuel combustion and environmental factors (i.e., wind direction, soil temperature). Notably, N fertilizer use (FN), energy consumption (E), and precipitation (P) jointly explained 84.3% of the spatial variation in DIN deposition, of which FN (27.2%) was the most important, followed by E (24.8%), and finally P (9.3%). The findings demonstrate that DIN deposition is regulated by precipitation mainly via anthropogenic N emissions, and this analysis provides decision-makers a novel view for N pollution abatement.
Collapse
Affiliation(s)
- X Zhan
- Institute of Soil and Water Conservation, Northwest A&F University, Yangling 712100, Shaanxi, China
| | - G Yu
- Synthesis Research Center of Chinese Ecosystem Research Network, Key Laboratory of Ecosystem Network Observation and Modeling, Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing 100101, China.
| | - N He
- Synthesis Research Center of Chinese Ecosystem Research Network, Key Laboratory of Ecosystem Network Observation and Modeling, Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing 100101, China
| | - B Jia
- Institute of Botany, Chinese Academy of Sciences, Beijing 100093, China
| | - M Zhou
- College of Ecology and Environmental Science, Inner Mongolia Agricultural University, Hohhot 010019, China
| | - C Wang
- College of Forestry, Northeast Forestry University, Harbin 150040, China
| | - J Zhang
- Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang 110016, China
| | - G Zhao
- Institute of Forest Ecology Environment and Protection, Chinese Academy of Forestry, Beijing 100091, China
| | - S Wang
- Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang 110016, China
| | - Y Liu
- Synthesis Research Center of Chinese Ecosystem Research Network, Key Laboratory of Ecosystem Network Observation and Modeling, Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing 100101, China
| | - J Yan
- South China Botany Garden, Chinese Academy of Sciences, Guangzhou 510650, China
| |
Collapse
|
44
|
Shen H, Chen HY, Jia B, Han GH, Zhang YS, Zeng XC. Characterization and expression analysis of microRNAs in Qira black sheep and Hetian sheep ovaries using Solexa sequencing. Genet Mol Res 2015. [PMID: 26214414 DOI: 10.4238/2015.july.3.11] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The role of microRNAs (miRNAs) in the regulation of mammalian reproduction has been demonstrated previously. However, only a few studies have assessed the role of miRNAs in the reproduction processes of sheep. The elucidation of miRNA expression profiles in the ovaries of different sheep breeds representing fecundity extremes will be useful in understanding the roles of miRNAs in sheep reproduction. In this study, two small RNA libraries were constructed from ovary tissue taken from Qira black sheep and Hetian sheep during the estrous period and then sequenced using the Solexa sequencing method. We obtained 9,565,212 and 9,563,426 high-quality reads from Qira black sheep and Hetian sheep, respectively. In total, 531 miRNAs, including 98 putative miRNAs, were identified. Among the conserved miRNAs, 125 known miRNAs were significantly differentially expressed in the Qira black sheep and Hetian sheep libraries, with 24 upregulated and 101 downregulated in the Hetian sheep compared to the Qira black sheep. Four differentially expressed miRNAs were analyzed using real-time quantitative PCR to validate the reliability of the Solexa sequencing results. These results provide a foundation for future research on the regulation of miRNAs in sheep fertility and enrich the sheep miRNA databases.
Collapse
Affiliation(s)
- H Shen
- College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, China
| | - H Y Chen
- School of Pharmacy, Shihezi University, Shihezi, Xinjiang, China
| | - B Jia
- College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, China
| | - G H Han
- College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, China
| | - Y S Zhang
- College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, China
| | - X C Zeng
- College of Animal Science and Technology, Shihezi University, Shihezi, Xinjiang, China
| |
Collapse
|
45
|
Fang Y, Zeng S, Fu X, Jia B, Li S, An X, Chen Y, Zhu S. Developmental competence in vitro and in vivo of bovine IVF blastocyst after 15 years of vitrification. Cryo Letters 2014; 35:232-238. [PMID: 24997841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND It is uncertain whether long-term cryopreservation affects embryonic development. OBJECTIVE This study was to investigate the effects of long-term cryopreservation on in vitro and in vivo developmental competence of bovine blastocysts. METHODS The blastocysts were randomly allocated into 3 groups based on the storage time: 0.5-year group, 1-year group and 15-years group. The thawed blastocysts were subjected to in vitro culture or embryo transplantation. RESULT Significantly lower survival rate (89.2%) and re-expansion rate (70.3%) of blastocysts were obtained from 15-years group compared with those of 0.5-year (97.5% and 87.5%) and 1-year (100% and 84.2%) groups (P < 0.05). There were no significant differences in the hatching rate (39.5% to 42.5%) among the three groups and the pregnancy rate between 1-year (35.0%) and 15-years (36.4%) groups. CONCLUSIONS Although in vitro developmental competence of the 15 years cryopreserved blastocysts was decreased slightly, the pregnancy outcome was not affected.
Collapse
Affiliation(s)
- Y Fang
- Key Laboratory of Animal Genetics, Breeding and Reproduction, Ministry of Agriculture and National Engineering Laboratory for Animal Breeding, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - S Zeng
- Key Laboratory of Animal Genetics, Breeding and Reproduction, Ministry of Agriculture and National Engineering Laboratory for Animal Breeding, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - X Fu
- Key Laboratory of Animal Genetics, Breeding and Reproduction, Ministry of Agriculture and National Engineering Laboratory for Animal Breeding, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - B Jia
- Key Laboratory of Animal Genetics, Breeding and Reproduction, Ministry of Agriculture and National Engineering Laboratory for Animal Breeding, College of Animal Science and Technology, China Agricultural University, Beijing, China
| | - S Li
- Bingjing AnBo Embryo Biotech Center, Beijing, China
| | - X An
- College of Biological Sciences, China Agricultural University, Beijing, China
| | - Y Chen
- College of Biological Sciences, China Agricultural University, Beijing, China
| | - S Zhu
- Key Laboratory of Animal Genetics, Breeding and Reproduction, Ministry of Agriculture and National Engineering Laboratory for Animal Breeding, College of Animal Science and Technology, China Agricultural University, Beijing, China
| |
Collapse
|
46
|
Deng M, Hofacer RD, Jiang C, Joseph B, Hughes EA, Jia B, Danzer SC, Loepke AW. Brain regional vulnerability to anaesthesia-induced neuroapoptosis shifts with age at exposure and extends into adulthood for some regions. Br J Anaesth 2014; 113:443-51. [PMID: 24431386 DOI: 10.1093/bja/aet469] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND General anaesthesia facilitates surgical operations and painful interventions in millions of patients every year. Recent observations of anaesthetic-induced neuronal cell death in newborn animals have raised substantial concerns for young children undergoing anaesthesia. However, it remains unclear why some brain regions are more affected than others, why certain neurones are eliminated while neighbouring cells are seemingly unaffected, and what renders the developing brain exquisitely vulnerable, while the adult brain apparently remains resistant to the phenomenon. METHODS Neonatal (P7), juvenile (P21), and young adult mice (P49) were anaesthetized with 1.5% isoflurane. At the conclusion of anaesthesia, activated cleaved caspase 3 (AC3), a marker of apoptotic cell death, was quantified in the neocortex (RSA), caudoputamen (CPu), hippocampal CA1 and dentate gyrus (DG), cerebellum (Cb), and olfactory bulb (GrO) and compared with that found in unanaesthetized littermates. RESULTS After anaesthetic exposure, increased AC3 was detected in neonatal mice in RSA (11-fold, compared with controls), CPu (10-fold), CA1 (three-fold), Cb (four-fold), and GrO (four-fold). Surprisingly, AC3 continued to be elevated in the DG and GrO of juvenile (15- and 12-fold, respectively) and young adult mice (two- and four-fold, respectively). CONCLUSIONS The present study confirms the findings of previous studies showing peak vulnerability to anaesthesia-induced neuronal cell death in the newborn forebrain. It also shows sustained susceptibility into adulthood in areas of continued neurogenesis, substantially expanding the previously observed age of vulnerability. The differential windows of vulnerability among brain regions, which closely follow regional peaks in neurogenesis, may explain the heightened vulnerability of the developing brain because of its increased number of immature neurones.
Collapse
Affiliation(s)
- M Deng
- Department of Anesthesiology, Children's Hospital of Fudan University, Shanghai 201102, China Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - R D Hofacer
- Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA Program in Neuroscience, University of Cincinnati, Cincinnati, OH 45221, USA
| | - C Jiang
- Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - B Joseph
- Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - E A Hughes
- Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA
| | - B Jia
- Heart Center, Children's Hospital of Fudan University, Shanghai 201102, China
| | - S C Danzer
- Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA Program in Neuroscience, University of Cincinnati, Cincinnati, OH 45221, USA Department of Anesthesiology, University of Cincinnati, Cincinnati, OH 45221, USA Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45221, USA
| | - A W Loepke
- Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA Program in Neuroscience, University of Cincinnati, Cincinnati, OH 45221, USA Department of Anesthesiology, University of Cincinnati, Cincinnati, OH 45221, USA Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45221, USA
| |
Collapse
|
47
|
Chen E, Xu D, Lan X, Jia B, Sun L, Zheng J, Peng H. A Novel Role of the STAT3 Pathway in Brain Inflammation-induced Human Neural Progenitor Cell Differentiation. Curr Mol Med 2013; 13:1474-84. [DOI: 10.2174/15665240113139990076] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 06/06/2013] [Accepted: 06/10/2013] [Indexed: 11/22/2022]
|
48
|
Han T, Zeng F, Li Z, Liu L, Wei M, Guan Q, Liang X, Peng Z, Liu M, Qin J, Zhang S, Jia B. Biochemical characterization of a recombinant pullulanase from Thermococcus kodakarensis
KOD1. Lett Appl Microbiol 2013; 57:336-43. [DOI: 10.1111/lam.12118] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2013] [Revised: 06/10/2013] [Accepted: 06/10/2013] [Indexed: 11/27/2022]
Affiliation(s)
- T. Han
- College of Plant Sciences; Jilin University; Changchun China
| | - F. Zeng
- College of Plant Sciences; Jilin University; Changchun China
| | - Z. Li
- College of Plant Sciences; Jilin University; Changchun China
| | - L. Liu
- College of Plant Sciences; Jilin University; Changchun China
| | - M. Wei
- College of Plant Sciences; Jilin University; Changchun China
| | - Q. Guan
- College of Plant Sciences; Jilin University; Changchun China
| | - X. Liang
- College of Plant Sciences; Jilin University; Changchun China
| | - Z. Peng
- College of Plant Sciences; Jilin University; Changchun China
| | - M. Liu
- College of Plant Sciences; Jilin University; Changchun China
| | - J. Qin
- College of Plant Sciences; Jilin University; Changchun China
| | - S. Zhang
- College of Plant Sciences; Jilin University; Changchun China
| | - B. Jia
- College of Plant Sciences; Jilin University; Changchun China
| |
Collapse
|
49
|
Li RY, Hui WQ, Jia B, Shi GQ, Zhao ZS, Shen H, Peng Q, Lv LM, Zhou QW, Li HT. The relationship between MHC-DRB1 gene second exon polymorphism and hydatidosis resistance of Chinese Merino (Sinkiang Junken type), Kazakh and Duolang sheep. Parasite 2011; 18:163-9. [PMID: 21678792 PMCID: PMC3671419 DOI: 10.1051/parasite/2011182163] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
The present study aimed at detecting the association of ovine major histocompatibility complex class II (Ovar II) DRB1 gene second exon and susceptibility or resistance to hydatidosis in three sheep breeds of Sinkiang. The MHC-DRB1 second exon was amplified by polymerase chain reaction (PCR) from DNA samples of healthy sheep and sheep with hydatidosis. PCR products were characterized by the restriction fragment length polymorphism (RFLP) technique. Five restriction enzymes, Mval, Haelll, Sacl, Sacll, Hin1l, were used, yielding 14 alleles and 31 restriction patterns. Frequencies of patterns Mvalbc, Hin1lab, Sacllab, Haelllde, Haellldf, Haellldd (P < 0.01) in Kazakh sheep, Saclab (P < 0.05) in Duolang sheep, and Haelllab, Haelllce, Haelllde, Haelllee (P < 0.01) in Chinese Merino (Sinkiang Junken type) sheep, were significantly higher in healthy sheep compared with infected sheep. These results indicated a strong association between these patterns and hydatidosis resistance. In contrast, the frequencies of Mvalbb, Saclaa, Hinl lbb, Haelllef (P < 0.01) and Haelllab (P < 0.05) in Kazakh sheep, Saclbb, Haelllae, Hin1lab (P < 0.05), Haelllaa, Haelllbe, Haelllef (P < 0.01) in Duolang sheep, Sacllaa (P < 0.05) and Haelllbd, Hin1lbb, Haelllcf, Haelllef (P < 0.01) in Chinese Merino sheep (Sinkiang Junken type) were significantly lower in healthy sheep compared with infected sheep. This indicated a strong association between these patterns and hydatidosis susceptibility. In addition, sheep with the pattern of Haelllef demonstrated a high hydatidosis susceptibility (P < 0.01) in all three breeds, while sheep with the pattern Haelllde demonstrated significant hydatidosis resistance (P < 0.01) in Kazakh and Chinese Merino sheep (Sinkiang Junken type). These results suggest that the Ovar-DRB1 gene plays a role in resistance to hydatidosis infection in the three sheep breeds.
Collapse
Affiliation(s)
- R Y Li
- College of Animal Science and Technology, Shihezi University, Shihezi, Sinkiang, 832003, P. R. China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Wu L, Zhang M, Sun M, Jia B, Wang X. Humoural Immune Responses to a Recombinant 16-kDa–38-kDa—ESAT-6 Mycobacterial Antigen in Tuberculosis. J Int Med Res 2011; 39:514-21. [PMID: 21672355 DOI: 10.1177/147323001103900219] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
The present study investigated the diagnostic value of a recombinant 38-kDa–16-kDa—early secreted antigenic target of 6 kDa (ESAT-6) Mycobacterium tuberculosis (MTB) fusion antigen in 105 patients with tuberculosis (TB), 25 non-TB pulmonary disease patients and 20 healthy individuals. Its diagnostic value was compared with the commercially available enzyme-linked immunosorbent assay kit, the TB-directly observed therapy (DOT) kit. In the controls, the rate of positive antibody response to the TB-DOT kit was significantly higher than that of the recombinant antigen. The area under the receiver operating characteristic curve was 0.751, and the optimum sensitivity and specificity for detecting antibody responses to the recombinant antigen were 65.4% and 84.8%, respectively. The recombinant 38-kDa–16-kDa—ESAT-6 MTB antigen was more effective than the TB-DOT kit in distinguishing between TB patients and controls, and may be an optimal combination of antigens to provide a useful tool for the sensitive and specific diagnosis of patients with TB.
Collapse
Affiliation(s)
- L Wu
- Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
| | - M Zhang
- Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
| | - M Sun
- Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
| | - B Jia
- Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
| | - X Wang
- Department of Respiratory Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
| |
Collapse
|